Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts

BACKGROUND: Systemic chemotherapy with gemcitabine and cisplatin is standard of care for patients with metastatic urothelial bladder cancer. However, resistance formation is common after initial response. The protein Src is known as a proto-oncogene, which is overexpressed in various human cancers....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Res Notes
Main Authors: Vallo, Stefan, Michaelis, Martin, Gust, Kilian M., Black, Peter C., Rothweiler, Florian, Kvasnicka, Hans-Michael, Blaheta, Roman A., Brandt, Maximilian P., Wezel, Felix, Haferkamp, Axel, Cinatl, Jindrich
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5039786/
https://ncbi.nlm.nih.gov/pubmed/27677700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13104-016-2256-3
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados